C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy [0.03%]
C- MET酪氨酸激酶受体：机制、临床应用及癌症治疗中的未来展望
Chenjing Zhu,Yue Li,Hanzi Xu et al.
Chenjing Zhu et al.
The high incidence and mortality rates of tumors have resulted in significant social and economic burdens, posing a major global threat to human life and societal development. In recent years, molecular targeted therapy for tumors has becom...
CAR T cell therapy beyond cancer: current status, challenges and future prospects [0.03%]
CAR-T细胞治疗在癌症之外的疾病中的应用：现状、挑战与未来前景
Saurabh Upadhyay,Sungwoo Cho,Kirti Upmanyu et al.
Saurabh Upadhyay et al.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized oncology, and its foundational logic-precise antigen recognition coupled with durable effector activity-extends naturally to chronic non-malignant diseases sustained by long-...
Hypoxia increases the activity of oncolytic adenoviruses through HIF-2α-stimulated E1A expression [0.03%]
缺氧通过HIF-2α刺激的E1A表达增强溶瘤腺病毒的活性
Egon J Jacobus,Véronique N Lafleur,Kerry D Fisher et al.
Egon J Jacobus et al.
Hypoxia, a hallmark of solid tumors, poses a significant challenge in cancer therapy due to its association with poor prognosis and resistance to conventional treatments. Oncolytic viruses represent a promising treatment strategy, as they s...
Cong Xie,Ying Wei,Chang Su et al.
Cong Xie et al.
Asthma is a heterogeneous chronic airway disease arising from a complex interplay of genetic susceptibility and environmental exposures. Key pathobiological features include dysregulated immune responses (particularly type 2 inflammation), ...
Cong Xie,Ying Wei,Chang Su et al.
Cong Xie et al.
Asthma is a heterogeneous chronic airway disease arising from a complex interplay of genetic susceptibility and environmental exposures. Key pathobiological features include dysregulated immune responses (particularly type 2 inflammation), ...
Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer [0.03%]
BRCA基因突变且HER2阴性的局部晚期或转移性乳腺癌患者中PARP抑制剂TSL-1502 II期随机试验
Bo Lan,Faliang Xu,Tao Sun et al.
Bo Lan et al.
Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized...
RNA methyltransferase 3 drives pancreatic acinar cell carcinoma growth and is a therapeutic target [0.03%]
胰腺管腺癌的生长驱动因子RNA甲基转移酶3及其作为治疗靶点的潜力
Shotaro Tatekawa,Tomoaki Hara,Sikun Meng et al.
Shotaro Tatekawa et al.
Pancreatic acinar cell carcinoma (ACC) is a rare and aggressive malignancy whose molecular basis remains poorly understood. N6-methyladenosine (m⁶A) RNA modification, mediated particularly through methyltransferase 3 (METTL3), has emerged ...
Calr-mediated calcium buffering: a molecular barrier to in vivo cardiac reprogramming [0.03%]
氯化钙介导的钙缓冲：体内心脏重编程的一个分子屏障
Johnny Kim,Hans R Schöler,Kee-Pyo Kim
Johnny Kim
Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer [0.03%]
代谢重塑中的翻译后修饰：对癌症代谢治疗和免疫治疗的启示
Si-Jie Chen,Shi-Wei Yue,Yun-Pu Zhang et al.
Si-Jie Chen et al.
Cancer metabolism is characterized by profound reprogramming, yet the mechanisms enabling rapid and precise adaptation remain incompletely understood. This review establishes post-translational modifications (PTMs) as the central processing...
Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study [0.03%]
一种新型高选择性ROCK2抑制剂(TDI01)治疗慢性移植物抗宿主病的多中心开放标签Ⅰb/Ⅱ期临床研究
Xiaodong Mo,Xuejun Zhang,Rong Guo et al.
Xiaodong Mo et al.
Chronic graft-versus-host disease (cGVHD) remains a major complication following allogeneic hematopoietic stem cell transplantation for long-term survival. Emerging evidence highlights Rho-associated coiled-coil kinase 2 (ROCK2) as a promis...